Connecting clinical care, data and research
PartnershipsContact
← Back to publications

RESEARCH PUBLICATION / 2025

Original Article

Different medications for diabetes and new onset rheumatoid arthritis

Comparative risk of rheumatoid arthritis between glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in type 2 diabetes.

Journal of autoimmunity

Citation & Authors

J Autoimmun. 2025;157:103493.

Fu-Shun Yen; Shiow-Ing Wang; Chii-Min Hwu; Chien-Wei Huang; Renin Chang; Chih-Cheng Hsu; James Cheng-Chung Wei

ABSTRACT · RESEARCH SUMMARY

Research summary

The matched TriNetX study found no significant difference in 7-year RA risk between GLP-1 receptor agonists and either DPP-4 inhibitors or basal insulin. SGLT2 inhibitors were associated with a lower RA risk than GLP-1 drugs (HR 0.88; 95% CI 0.80–0.96). This observational comparison is insufficient to support using glucose-lowering drugs as preventive treatment for RA.

Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗